Abstract
Background
Innate monocytes can adopt dynamic “memory” states ranging from low-grade inflammation to pathogenic exhaustion, dependent upon signal strength and history of challenges. Low-grade inflammatory monocytes facilitate the pathogenesis of chronic inflammatory diseases, while exhausted monocytes drive the pathogenesis of severe sepsis. Although clinical and basic studies suggest the conservation of key features of exhausted monocytes from human and murine sepsis, systems analyses of monocyte exhaustion among human and murine monocytes are lacking.
Methods
We performed cross examination of septic monocytes scRNAseq data recently collected from human sepsis patients as well as experimental septic mice, in reference to monocytes experimentally exhausted in vitro. Furthermore, we performed pseudo-time analyses of in vitro programmed monocytes following prolonged challenges causing either low-grade inflammation or exhaustion. Additional comparative analyses of low-grade inflammatory monocytes were performed with scRNAseq data from selected human patients with chronic low-grade inflammatory diseases.
Results
Our systems analyses reveal key features of monocyte exhaustion including reduced differentiation, pathogenic inflammation and immune suppression that are highly conserved in human and murine septic monocytes, and captured by in vitro experimental exhaustion. Pseudo-time analyses reveal that monocytes initially transition into a less-differentiated state with proliferative potential. The expansion of proliferative monocytes can be observed not only in experimentally challenged monocytes, but also in tissues of murine sepsis and human septic blood. We observed that monocytes similarly transition into the less-differentiated state when challenged with a subclinical dose endotoxin under chronic inflammatory conditions. Instead of being exhausted, monocytes with prolonged challenges with super-low dose endotoxin bifurcate into the low-grade inflammatory immune-enhancing or the chemotactic/adhesive state, often see in atherosclerosis or auto-immune diseases.
Conclusions
Key features of monocyte memory dynamics are identified and conserved in human and murine monocytes, which can be captured by prolonged challenges of innate signals with varying signal strength.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Emerging studies reveal the presence of innate immune memory, a complex process during which innate leukocytes adopt altered activation states depending upon the signal strength and history of challenges [1]. Basic and translational studies suggest that monocyte memory dynamics occur in both human and murine monocytes, with shared features of altered activation dynamics ranging from priming, tolerance to exhaustions. However, comparative analyses of monocyte memory dynamics have not been systematically conducted.
In the context of signal strength and history-dependent memory of lipopolysaccharide (LPS), our group defined that persistent challenges of monocytes with super-low dose LPS drive the sequential activation of cell proliferation, inflammatory activation and adhesion [2, 3], which correspond to the pathogenesis of chronic inflammatory diseases, such as atherosclerosis [2]. In contrast, prolonged challenges with higher doses of LPS promote monocyte proliferation and immune exhaustion, as reflected in the tripartite features of reduced differentiation; immune suppression; and pathogenic inflammation [4]. Pathologically, less-mature exhausted monocytes fail to differentiate into functional macrophages with effective clearance of pathogens and cellular debris. Exhausted monocytes have reduced expression of immune-enhancing mediators, such as CD86, CD80, and MHCII, while highly potent in expressing immune-suppressive mediators such as PD-L1 that collectively compromise immune defense against pathogens. Adding further damage to the host, exhausted monocytes express pathogenic inflammatory mediators including various cytokines as well as CD38, an NAD depleting enzyme [4]. These key exhausted features have been increasingly observed in experimental sepsis as well as human sepsis patients [5,6,7]. Despite their conserved natures, currently there is no available comparative analysis to cross-examine monocyte exhaustion among murine and human systems.
To fill this critical void, we aim to perform comparative analyses of key exhaustion features of monocytes from murine and human sepsis, in comparison with the in vitro experimental model of monocyte exhaustion. Based on recent scRNAseq data from human sepsis [8,9,10,11] and murine model of cecal ligation and puncture sepsis [12], we cross-examined key gene expression profiles representing the tripartite characteristics of monocyte exhaustion identified in the in vitro model of exhaustion. To determine potential mechanisms, we performed pseudo-time analyses of monocyte exhaustion based on our existing scRNAseq analyses of exhausted monocytes, mapping out the trajectory of monocyte memory dynamics dependent on signal strength. We identified key representative genes involved in proliferation, pathogenic inflammation and immune suppression similarly modulated in experimentally exhausted monocyte in vitro, as well as experimental sepsis and human septic patients. To complement the analyses of low-grade inflammatory monocytes challenged with chronic weak signals associated with chronic inflammatory diseases, such as lupus, we cross-examined key low-grade inflammatory gene signatures from scRNAseq data collected from human lupus patients. Collectively, our systems analyses reveal highly conserved natures of monocyte exhaustion across murine and human septic monocytes in vivo and in vitro, as well as shared features of low-grade inflammation from monocytes collected from auto-immune disease patients.
Materials and methods
Experimental data
The experimental data used in this study were obtained either from publicly available databases or previously published in our own laboratory. Murine data were described in our previous publication [4] and deposited under the accession number GSE190856. Human data were obtained from recently published sources [8,9,10,11], including the Single Cell Portal SCP548, Array Express E-MTAB-9357, GSE148020, and GSE198616. Murine monocytes harvested from septic heart were as reported [12].
Data analysis
The data obtained were preprocessed and analyzed using the Seurat package as we described previously [4]. Briefly, the raw data were normalized using the ‘LogNormalize’ function, and variable genes were identified using the ‘FindVariableFeatures’ function with the default parameters. Principal component analysis (PCA) was performed using the variable genes, and the top 10–20 principal components were used for clustering analysis. The ‘FindClusters’ function was used to cluster the cells based on their gene expression profiles with a resolution around 0.1. The clusters were visualized using Uniform Manifold Approximation and Projection (UMAP) and default clustering by Seurat.
Differential Expression Genes (DEG) analysis was conducted under Seurat default setting. Dot plot analyses were conducted to examine represented genes defining fundamental characteristics of distinct memory monocyte subsets.
Dot plots displaying the relative expression levels of selected targets were generated with the Seurat software through the unbiased default setting, representing both the percentages of target gene expression among the cell sub-populations as well as normalized expression levels of the target gene as we previously described [4]. Key selected target genes differentially expressed in a target cluster were obtained for each cluster using the non-parametric Wilcoxon rank sum test in R. The dot size represents the percentage of cell population expressing the target gene and the dot color intensity represents the normalized expression level of the given target.scVelo (v0.2.5) analyses were performed on murine scRNAseq data previously deposited and published [4], which were then aligned by Cellranger (v3.1.0), reevaluated by Velocyto (v0.17), and then sent to scVelo to predict the vectors.
GO analyses were conducted using the Enrichment Gene Ontology database to identify the most enriched and appropriate GO terms for the DEG analysis results as we previously described [2].
Results
Three cardinal features of monocyte exhaustion recapitulated in vitro through prolonged stimulation with high dose bacterial endotoxin
Clinical studies with human septic patients and animal studies of sepsis increasingly suggest the expansion of less-matured monocytes with pathogenic inflammatory and immune-suppressive characteristics [13]. We recently published the generation of exhausted monocytes through in vitro culture of murine bone marrow monocytes with persistent challenges of higher dose endotoxin [4]. However, key genes involved in the exhaustion and underlying mechanisms are not thoroughly understood. To further systematically characterize the exhausted monocytes, we focused on classes of genes selectively involved in modulating cell differentiation/proliferation, pathogenic inflammation, and immune suppression, three pillars of monocyte exhaustion in sepsis.
As shown in Fig. 1A, in vitro exhausted monocytes (both of the Ly6C+ and Ly6C++ groups) potently express higher levels of genes involved in proliferation (elevated Plac8, Plaur, Stmn1, Hmmr, Mki67 and reduced Cdc14b), pathogenic inflammation (Cd38, Bst1, Itgam, Icam1), and immune suppression (elevated Cd274, Slpi, CD24a and reduced Cd86, Icosl and H2-Aa). Among genes involved in cell proliferation, STMN1 interacts with microtubules and is an indicator of mitosis, while MKI67 condenses in the nucleus during mitosis. PLAC8 and PLAUR are also known to be involved in cell proliferation [14,15,16]. On the other hand, CDC14B was recently shown to promote cell differentiation and prevent excessive proliferation [17]. Among immune suppressive genes, CD274 (PD-L1) protein potently suppresses T cell functions [18], SLPI and CD24A proteins are involved in anti-inflammatory immune suppression [19,20,21]. In contrast, CD86, ICOSL and H2-Aa proteins are involved in enhancing adaptive immune functions [22,23,24]. Among pathogenic inflammatory genes, both CD38 and BST1 proteins lead to the depletion of cellular metabolic fuel NAD and the generation of inflammatory secondary mediators [25, 26]. CD11B and ICAM1 proteins are involved in inflammatory adhesion of monocytes to vasculatures [27, 28]. Furthermore, as less-differentiated monocytes, in vitro exhausted monocytes lose phagocytic receptors Trem2, Fcgr1 and immune modulator Cd200r1. Collectively, in vitro exhausted monocytes exhibit altered gene expression profiles of reduced differentiation, enhanced pathogenic inflammation and immune suppression.
To gain further mechanistic insights of their generation, we looked at key signaling components and transcription factors modulating monocyte behaviors. Proteasomes have been known to be elevated in activated monocytes [29]. We observed elevation of proteasome components such as Psmb6 and Psmb10 in exhausted monocytes. SOCS3 protein is known to be elevated in “tolerant” monocytes with reduced expression of immune-enhancing mediators [30], and we observed elevated Socs3 in exhausted monocytes. In terms of transcription factors, C/EBPα and C/EBPβ proteins are known to be differentially involved in monocyte differentiation and activation, with C/EBPα facilitating cell differentiation [31, 32] and C/EBPβ promoting inflammatory activation [33]. C/EBPα is also involved in suppressing the generation of myeloid derived suppressor cells [34]. We observed that C/ebpα is reduced in exhausted monocytes, correlated with reduced differentiation. In contrast, C/ebpβ is elevated in exhausted monocytes, corresponding to elevated pathogenic inflammation. IRF5 protein is a key transcription factor promoting the expression of immune-enhancing genes, such as Cd86, H2-Aa and Cd40 [35,36,37]. Exhausted monocytes exhibit levels of Irf5, corresponding to reduced expression of Cd86 and H2-Aa.
One of the advantages in analyzing single cell data is the potential to perform pseudo-time analyses for their ontogeny and trajectory. We then performed scVelo analyses of monocytes with prolonged challenges of either super-low dose or high dose LPS, or an anti-inflammatory agent 4-PBA together with super-low dose LPS (Fig. 1B). Our analyses reveal that cells initially prompted into the proliferative, less differentiated state following either super-low or high dose LPS. Subsequently, monocytes track into the exhausted Ly6C++ monocytes and gradually into the Ly6C+ exhausted monocytes with lower proliferating potential.
In contrast, monocytes challenged with prolonged signals of super-low dose LPS bifurcate into a totally different direction. Our analyses reveal that low-dose LPS treated monocytes first move into the Ly6C++ monocytes with growth-promoting and immune-enhancing state, and then into the Ly6C+ chemotactic and adhesive low-grade inflammatory state [2]. In our previous experimental studies, we applied anti-inflammatory mediator 4-PBA and reported that 4-PBA blocked the generation of inflammatory monocytes induced by super-low dose LPS. 4-PBA has also been independently shown to potently reduce atherosclerosis [7, 38, 39], and its mechanisms of action require future clarification. Although 4-PBA may have diverse functions, the usage of 4-PBA in this particular system of monocyte dynamics can robustly arrest monocyte activation. In the lens of monocyte dynamics, monocyte arrested by 4-PBA provides a novel reference point for examining monocyte activation dynamics, in guiding future studies of monocyte single cell trajectories. We superimposed 4-PBA plus low-dose LPS scRNAseq onto the scVelo map, and further validated that 4-PBA arrests low-dose LPS treated monocytes into the proliferating or anti-inflammatory state.
Septic human monocytes share similar gene expression profiles of monocyte exhaustion
With recently available scRNAseq data of human septic monocytes [9], we then performed comparative analyses of key genes representing monocyte exhaustion among murine and human systems. Human monocytes can be separated into classical, intermediate, and non-classical subpopulations by evaluating the levels of the CD14 and FCGR3A (CD16) markers. We analyzed the relative expression of above-described genes identified in exhausted murine monocytes among human monocyte subsets from healthy and septic patients [9] (Fig. 2).
As reported independently, septic patients exhibit a reduction of the non-classical monocytes, and an expansion of the intermediate and classical monocytes [9, 40]. We then further separately compared gene expression profiles based on the scRNAseq clusters of each monocyte subset. As shown in Fig. 2, the less-differentiated signatures (elevated STMN1, MKI67 and reduced CDC14B) can be seen to be elevated in septic non-classical monocytes, suggesting the conserved characteristic of reduced differentiation and proliferative potential of septic monocytes. The immune-enhancing genes such as CD86, ICOSL and HLA-DQA1 are all reduced suggesting the development of immune suppression. Key transcription factor C/EBPα involved in differentiation as well as the transcription factor IRF5 involved in immune-enhancing gene expression were both reduced in septic non-classical monocytes. Among the expanded intermediate and the classical subsets, septic monocytes also exhibit elevated levels of proliferative genes (STMN1, MKI67). Furthermore, additional pathogenic inflammatory genes are elevated which include CD38, BST1, ICAM1, ITGAM, as well as the immune suppression gene CD274 (PD-L1). Mechanistically, proteasome components such as PSMB6 and 10 as well as the pathogenic inflammatory transcription factor C/EBPβ were all elevated in the intermediate and classical subsets of septic monocytes as compared to healthy subsets (Fig. 2). Together, our targeted analyses confirm that human septic monocytes shared the cardinal features of experimentally exhausted monocytes with reduced differentiation; pathogenic inflammation and immune suppression, key attributes leading to compromised host defense and multi-organ injuries.
Cardinal features of monocyte exhaustion identified are also conserved in the experimental model of animal sepsis
During the preparation of this manuscript, an independent study appeared in Nature Metabolisms that provided single cell profiling of infiltrating macrophages and monocytes in murine septic heart tissues [12]. The authors focused on interpreting the alterations of tissue macrophages in a time-dependent fashion following the initial insult of cecal ligation and puncture, with an initial depletion of TREM2 positive macrophages and rapid restoration of TREM2 macrophages 7–21 days post the initial sepsis. Although the authors did not elaborate, we noticed that there was a sustained expansion of infiltrating monocytes within the septic heart lasting throughout the 21-day observation period and never restore back to the baseline. There is also an expansion of a highly proliferative “cycling cell” population that is also sustained throughout the 21-day post-sepsis period.
We then analyzed the monocyte gene expression profiles over time following the onset of murine sepsis. As shown in Fig. 3, we observed that at day 3 post sepsis, infiltrating monocytes within the heart underwent robust exhaustion reflected in pathogenic inflammation (elevated Cd38, Bst1, ItgaM) and immune suppression (reduced Cd86, and elevated Cd274), as well as reduced differentiation and enhanced proliferative potential (elevated Stmn1). Many of these key features lasted throughout the 21-day period. Mechanistically, we observed similar activation of C/ebpβ, and reduction of C/ebpα as well as Irf5. Collectively, our systems analyses reveal highly conserved exhaustion profiles of monocytes from human septic patients, murine experimental sepsis, as well as in vitro exhausted monocytes (Fig. 3C). Similar profiles of exhaustion can also be seen in the cycling monocytes (Fig. 3).
COVID-induced monocyte alterations share key features of monocyte exhaustion seen in sepsis
There are rising interests with regard to COVID-related immune alterations, which may share some similarity with human sepsis. We, therefore, further examined whether the key exhaustion features may similarly exist in monocytes harvested from COVID patients.
As reported through the scRNAseq data, COVID patients similarly experience a reduction of the non-classical population, and an expansion of the classical monocyte population. We, therefore, specifically compared the classical monocytes among healthy and COVID patients. As shown in Fig. 4, we observed similar profiles of enhanced proliferative potential (elevated STMN1 and MKI67), pathogenic inflammation (elevated CD38, BST1, ITGAM), and immune suppression (elevated PD-L1, SLPI, CD24 and reduced ICOSL). Mechanistically, we observed elevated proteasome components and increased C/EBPβ in COVID patient monocytes. Our data validate that key signatures of monocyte exhaustion are conserved in patients with systemic inflammation caused by COVID-19 infection.
Auto-immune-monocyte alterations have overlapping yet distinct characteristics as compared to sepsis monocytes
We then turned our attention to chronic low-grade inflammatory diseases, and examined whether monocytes from humans with chronic diseases may have distinct alteration features of monocytes. This is based on our data that monocytes with prolonged challenges with low-grade inflammatory signals bifurcate into a distinct low-grade inflammatory state [3], reflected in pathogenic inflammation and immune-enhancing characteristics.
To test this, we examined recently published scRNAseq data collected from human patients with Vogt–Koyanagi–Harada (VKH) disease, which is a systemic autoimmune disorder characterized by a dysregulated immune response resulting from altered monocyte phenotype and function [8]. Patients with VKH disease exhibit hyperactivity of monocytes and elevated secretion of pro-inflammatory cytokines, which are implicated in the observed inflammation in affected tissues. While the exact cause of VKH disease remains unknown, it is believed to result from a combination of genetic and environmental factors.
We clustered scRNAseq data into three clusters based on CD14 and CD16 expression levels into the non-classical, intermediate, and classical subsets. We then examined representative genes in the categories of pathogenic inflammation, proliferative potential and immune modulation (Fig. 5). In common with the septic patient monocytes, VHK patient monocytes also have the elevated pathogenic inflammation feature with increased expression of CD38, BST1, ITGAM. However, in contrast to septic monocytes, we observed that VKH patient monocytes do not exhibit consensus feature of proliferation, suggesting the emergency hematopoiesis and reduced differentiation is not a striking feature of this disease. Furthermore, unlike the septic monocytes, VKH patient monocytes express elevated immune-enhancing genes, such as CD86, suggesting the development of the low-grade immune-enhancing phenotype in these patients. Mechanistically, these patient monocytes exhibit an overall elevation of C/EBPα, C/EBPβ and IRF5. Our analyses reveal that chronic auto-immune types of diseases exhibit distinct features of monocyte reprogramming, with enhanced pathogenic inflammation and immune enhancing characteristics, resembling low-grade inflammatory monocytes we identified in the murine system [3].
We further examined another form of human auto-immune disease [10]. Behcet’s disease (BD) is a more severe chronic systemic inflammatory disorder that often presents with recurrent oral/genital ulceration and skin lesions, and in severe cases, can result in multi-organ malfunctions leading to significant morbidity and mortality. Based on recently published scRNAseq data of monocytes collected from BD patients, we similarly grouped BD samples into non-classical; intermediate; and classical clusters, and examined key signatures we identified in this manuscript (Fig. 6). Similar to VHK patients and distinct from septic or COVID-19 patients, the non-classical and intermediate BD patient monocytes do not have a proliferative signature. The pathogenic inflammatory feature, however, is evident from BD patient monocytes with elevated levels of CD38, BST1, ITGAM. In contrast to the VHK patients, the intermediate and classical monocytes from BD patients showed higher expression of pathogenic inflammatory genes, as well as reduced immune-enhancing genes, similar to septic monocytes. The “hybrid nature” of semi-exhausted monocytes from the BD patients may correlate with the severe multi-organ dysfunctions.
Discussion
Our comparative analyses reveal several key principles of monocyte dynamics conserved from human and murine systems. First, prolonged and overwhelming challenges as seen in sepsis initiate and sustain an exhaustion phenotype characterized by reduced differentiation; pathogenic inflammation and immune suppression, which can be recapitulated with prolonged high dose LPS treatment. Second, our pseudo-time analyses suggest that monocytes first halt differentiation and gain proliferative characteristics upon the initial challenge, before bifurcating into either the exhausted state when faced with severe challenges or the low-grade immune-enhancing state when faced with mild challenges. Third, our study reveals conserved molecular circuitry potentially responsible for controlling the memory dynamics in both murine and human monocytes. At the translational level, our analyses demonstrate that blood monocytes from septic and severe COVID patients share overlapping features of exhaustion. In contrast, monocytes from chronic autoimmune patients share distinct features of low-grade inflammation.
Our systems study complements and advances the existing notion regarding the functional characteristics of exhausted monocytes observed in both murine and human sepsis. Previous studies reported the emergence of pre-mature myeloid cells during sepsis, with reduced differentiation and immune suppressive functions, commonly referred as myeloid derived suppressor cells (MDSC) [41]. However, since MDSCs represent a mixture of functionally defined suppressor cells, it has been challenging to clearly illustrate precise cell subsets and underlying mechanisms based on these studies. Recent advances in single cell sequencing analyses ushered in a new era amassing enormous amount of gene expression data from human patients as well as experimental animal. Although these studies are extremely information-rich, they are less informative without a proper integration with conventional hypothesis-based studies. There is an urgent need to make a clear and better sense of these large data sets and define key causal nodes closely related to the pathogenesis of sepsis as well as other inflammatory diseases. To this regard, we examined key targets genes with relevant conventional pathogenesis perspectives from the large data sets representing human sepsis as well as animal experimental sepsis. These target genes were selectively mined from the large data sets to represent key principles of monocyte exhaustion, namely, enhanced proliferation; pathogenic inflammation and immune suppression, known to play causal roles during sepsis pathogenesis. We demonstrate that these target genes can be conservatively captured from previously published scRNAseq data sets collected from human sepsis patients. Comparatively, we demonstrate that these key gene expression features can also be captured from the scRNAseq data sets from the murine model of sepsis. Our comparative analyses posit that these key gene signatures should be further examined through the conventional hypothesis-driven experimental approaches in the future, with well-defined healthy and control patients, to potentially serve as diagnostic markers for sepsis.
Although previous approaches eluded to the proliferative and pathogenic nature of septic myeloid cells, underlying mechanisms are still poorly defined. Taking advantage of single cell sequencing data, we were able to perform pseudo-time trajectory analyses to pinpoint the temporal ontogeny of septic monocytes. Our analyses reveal an intriguing clue indicating that septic monocytes initially undergo halted differentiation and re-gain proliferative potential, correlating with previously identified “emergency hematopoiesis” during sepsis [42]. Following the initial de-differentiation, septic monocytes subsequently gain the next set of exhaustion features including pathogenic inflammation and immune suppression. Based on our analyses, future experimental validation is warranted to test whether cell proliferation inhibitor may block subsequent monocyte exhaustion, and whether such strategy can be used for treating sepsis.
Our data further reveal that the initial de-differentiation process is a common gateway for monocytes facing endotoxin challenges with varying signal strength. Our scVelo analyses reveal that monocytes with subclinical super-low dose LPS challenge similarly go through the initial de-differentiation step. This is consistent with previous genetic and functional studies reporting that enhanced clonal hematopoiesis is closely associated with exacerbated atherosclerosis [43,44,45]. In contrast to the higher dose LPS challenge, super-low dose LPS nudges monocytes to the low-grade inflammatory states, sequentially from the initial de-differentiated state to immune-enhancing, pro-growth state and the late mature state with inflammatory and adhesive properties. The signatures of chronic inflammatory monocyte states can be partially seen in monocytes from chronic human diseases such as atherosclerosis and various forms of auto-immune diseases. Our comparative analysis reconciles previous studies that reveal persistent low-grade “metabolic endotoxemia” in circulation (~ 1–100 pg/ml) as a closely related risk factor for chronic metabolic diseases, such as diabetes and atherosclerosis [46,47,48,49]. In contrast, higher doses of circulating endotoxin (~ ng/ml) are present in human septic patients [50, 51].
Taken together, our systems analysis not only reveals conserved features of monocyte exhaustion, but also provide important insights into the molecular mechanisms underlying monocyte exhaustion in sepsis, highlighting alterations in gene expression profiles related to cell differentiation/proliferation, pathogenic inflammation, and immune suppression, as well as the involvement of specific signaling components and transcription factors. However, our current work is limited in scope by attempting to reconcile emerging scRNAseq studies amassing large amount of data sets with hypothesis-driven studies on selected targets utilizing well-controlled human or experimental animals. Although our comparative studies comparing in vitro and in vivo scRNAseq data suggest some intriguing principles and reveal promising target genes likely representing key signatures of monocyte exhaustion or low-grade inflammation, future independent in vivo studies with well-controlled experimental groups should be pursued to provide causative validation based on this initial comparative analyses. Further understanding of these mechanisms through future studies may potentially lead to the development of novel therapeutic strategies for sepsis and other inflammatory conditions involving monocyte dysfunction.
Data availability
This study utilized data sets publicly available as indicated in the “Materials and methods” section.
References
Geng S, Pradhan K, Li L. Signal-strength and history-dependent innate immune memory dynamics in health and disease. Handb Exp Pharmacol. 2022;276:23–41.
Geng S, Zhang Y, Yi Z, Lu R, Li L. Resolving monocytes generated through TRAM deletion attenuate atherosclerosis. JCI Insight. 2021;4(2): e122939.
Lee J, Geng S, Li S, Li L. Single cell RNA-Seq and machine learning reveal novel subpopulations in low-grade inflammatory monocytes with unique regulatory circuits. Front Immunol. 2021;12: 627036.
Pradhan K, Yi Z, Geng S, Li L. Development of exhausted memory monocytes and underlying mechanisms. Front Immunol. 2021;12: 778830.
Maheshwari D, Kumar D, Jagdish RK, Nautiyal N, Hidam A, Kumari R, et al. Bioenergetic failure drives functional exhaustion of monocytes in acute-on-chronic liver failure. Front Immunol. 2022;13: 856587.
Naler LB, Hsieh YP, Geng S, Zhou Z, Li L, Lu C. Epigenomic and transcriptomic analyses reveal differences between low-grade inflammation and severe exhaustion in LPS-challenged murine monocytes. Commun Biol. 2022;5:102.
Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci USA. 2009;106:6303–8.
Hu Y, Hu Y, Xiao Y, Wen F, Zhang S, Liang D, et al. Genetic landscape and autoimmunity of monocytes in developing Vogt–Koyanagi–Harada disease. Proc Natl Acad Sci USA. 2020;117:25712–21.
Reyes M, Filbin MR, Bhattacharyya RP, Billman K, Eisenhaure T, Hung DT, et al. An immune-cell signature of bacterial sepsis. Nat Med. 2020;26:333–40.
Zheng W, Wang X, Liu J, Yu X, Li L, Wang H, et al. Single-cell analyses highlight the proinflammatory contribution of C1q-high monocytes to Behcet’s disease. Proc Natl Acad Sci USA. 2022;119: e2204289119.
Lee JW, Su Y, Baloni P, Chen D, Pavlovitch-Bedzyk AJ, Yuan D, et al. Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19. Nat Biotechnol. 2022;40:110–20.
Zhang K, Wang Y, Chen S, Mao J, Jin Y, Ye H, et al. TREM2(hi) resident macrophages protect the septic heart by maintaining cardiomyocyte homeostasis. Nat Metab. 2023;5:129–46.
Darden DB, Kelly LS, Fenner BP, Moldawer LL, Mohr AM, Efron PA. Dysregulated immunity and immunotherapy after sepsis. J Clin Med. 2021;10(1742):1–13.
Lee H, Hikasa K, Umesono Y, Hayashi T, Agata K, Shibata N. Loss of plac8 expression rapidly leads pluripotent stem cells to enter active state during planarian regeneration. Development. 2022;149: dev199449.
Jia Y, Ying X, Zhou J, Chen Y, Luo X, Xie S, et al. The novel KLF4/PLAC8 signaling pathway regulates lung cancer growth. Cell Death Dis. 2018;9:603.
Portelli MA, Siedlinski M, Stewart CE, Postma DS, Nieuwenhuis MA, Vonk JM, et al. Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels. FASEB J. 2014;28:923–34.
Villarroya-Beltri C, Martins AFB, Garcia A, Gimenez D, Zarzuela E, Novo M, et al. Mammalian CDC14 phosphatases control exit from stemness in pluripotent cells. EMBO J. 2023;42: e111251.
Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6:74.
Nugteren S, Samsom JN. Secretory Leukocyte Protease Inhibitor (SLPI) in mucosal tissues: protects against inflammation, but promotes cancer. Cytokine Growth Factor Rev. 2021;59:22–35.
Shapira S, Ben Shimon M, Hay-Levi M, Shenberg G, Choshen G, Bannon L, et al. A novel platform for attenuating immune hyperactivity using EXO-CD24 in COVID-19 and beyond. EMBO Mol Med. 2022;14: e15997.
Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 2009;323:1722–5.
Nolan A, Kobayashi H, Naveed B, Kelly A, Hoshino Y, Hoshino S, et al. Differential role for CD80 and CD86 in the regulation of the innate immune response in murine polymicrobial sepsis. PLoS One. 2009;4: e6600.
Wikenheiser DJ, Stumhofer JS. ICOS co-stimulation: friend or foe? Front Immunol. 2016;7:304.
Wieczorek M, Abualrous ET, Sticht J, Alvaro-Benito M, Stolzenberg S, Noe F, et al. Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. Front Immunol. 2017;8:292.
Piedra-Quintero ZL, Wilson Z, Nava P, Guerau-de-Arellano M. CD38: an immunomodulatory molecule in inflammation and autoimmunity. Front Immunol. 2020;11: 597959.
Malavasi F, Deaglio S, Ferrero E, Funaro A, Sancho J, Ausiello CM, et al. CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity. Mol Med. 2006;12:334–41.
Lin QY, Bai J, Zhang YL, Li HH. Integrin CD11b contributes to hypertension and vascular dysfunction through mediating macrophage adhesion and migration. Hypertension. 2023;80:57–69.
Kevil CG, Patel RP, Bullard DC. Essential role of ICAM-1 in mediating monocyte adhesion to aortic endothelial cells. Am J Physiol Cell Physiol. 2001;281:C1442–7.
Qureshi N, Morrison DC, Reis J. Proteasome protease mediated regulation of cytokine induction and inflammation. Biochim Biophys Acta. 2012;1823:2087–93.
Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 2009;30:475–87.
Timchenko NA, Harris TE, Wilde M, Bilyeu TA, Burgess-Beusse BL, Finegold MJ, et al. CCAAT/enhancer binding protein alpha regulates p21 protein and hepatocyte proliferation in newborn mice. Mol Cell Biol. 1997;17:7353–61.
Yeamans C, Wang D, Paz-Priel I, Torbett BE, Tenen DG, Friedman AD. C/EBPalpha binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment. Blood. 2007;110:3136–42.
Huber R, Pietsch D, Panterodt T, Brand K. Regulation of C/EBPbeta and resulting functions in cells of the monocytic lineage. Cell Signal. 2012;24:1287–96.
Hashimoto A, Sarker D, Reebye V, Jarvis S, Sodergren MH, Kossenkov A, et al. Upregulation of C/EBPalpha inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer. Clin Cancer Res. 2021;27:5961–78.
Calise J, Marquez Renteria S, Gregersen PK, Diamond B. Lineage-specific functionality of an interferon regulatory factor 5 lupus risk haplotype: lack of B cell intrinsic effects. Front Immunol. 2018;9:996.
Alzaid F, Lagadec F, Albuquerque M, Ballaire R, Orliaguet L, Hainault I, et al. IRF5 governs liver macrophage activation that promotes hepatic fibrosis in mice and humans. JCI Insight. 2016;1: e88689.
Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol. 2011;12:231–8.
Erbay E, Babaev VR, Mayers JR, Makowski L, Charles KN, Snitow ME, et al. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med. 2009;15:1383–91.
Lynn EG, Lhotak S, Lebeau P, Byun JH, Chen J, Platko K, et al. 4-Phenylbutyrate protects against atherosclerotic lesion growth by increasing the expression of HSP25 in macrophages and in the circulation of Apoe(−/−) mice. FASEB J. 2019;33:8406–22.
Baudesson de Chanville C, Chousterman BG, Hamon P, Laviron M, Guillou N, Loyher PL, et al. Sepsis triggers a late expansion of functionally impaired tissue-vascular inflammatory monocytes during clinical recovery. Front Immunol. 2020;11:675.
Schrijver IT, Theroude C, Roger T. Myeloid-derived suppressor cells in sepsis. Front Immunol. 2019;10:327.
Abidin BM, Hammami A, Stager S, Heinonen KM. Infection-adapted emergency hematopoiesis promotes visceral leishmaniasis. PLoS Pathog. 2017;13: e1006422.
Tall AR, Fuster JJ. Clonal hematopoiesis in cardiovascular disease and therapeutic implications. Nat Cardiovasc Res. 2022;1:116–24.
Pardali E, Dimmeler S, Zeiher AM, Rieger MA. Clonal hematopoiesis, aging, and cardiovascular diseases. Exp Hematol. 2020;83:95–104.
Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–21.
Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr. 2007;86:1286–92.
Epstein H, Grad E, Golomb M, Koroukhov N, Edelman ER, Golomb G, et al. Innate immunity has a dual effect on vascular healing: suppression and aggravation of neointimal formation and remodeling post-endotoxin challenge. Atherosclerosis. 2008;199:41–6.
Goto T, Eden S, Nordenstam G, Sundh V, Svanborg-Eden C, Mattsby-Baltzer I. Endotoxin levels in sera of elderly individuals. Clin Diagn Lab Immunol. 1994;1:684–8.
Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.
Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, et al. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med. 2010;38:72–83.
Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999;180:1584–9.
Acknowledgements
This study was supported partly by the National Institute of Health grants R01 AI172133 and R01HL163948 to LL.
Author information
Authors and Affiliations
Contributions
LL and ZY designed the analyses. ZY analyzed the data. LL, ZY, and SG wrote the manuscript. All authors reviewed and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
There is no conflict of interest related to this publication.
Additional information
Responsible Editor: John Di Battista.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Yi, Z., Geng, S. & Li, L. Comparative analyses of monocyte memory dynamics from mice to humans. Inflamm. Res. 72, 1539–1549 (2023). https://doi.org/10.1007/s00011-023-01762-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00011-023-01762-8